Tempo Therapeutics has filed a notice of an exempt offering of securities to raise $16,793,660.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Tempo Therapeutics is raising up to $16,793,660.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Westbrook Weaver played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Tempo Therapeutics
Tempo Therapeutics, headquartered in San Diego, California, is pioneering a new era in tissue engineering biotechnology, using our proprietary MAP material science technology. Using MAP technology, Tempo is building functional tissue and organs within patients, in real time, to treat disease, and developing next-generation vaccine technologies that are shelf stable, stockpile-able, and protect against multiple diseases with a single injection. Our mission is to use MAP material technology to enable the future of medicine.
To learn more about Tempo Therapeutics, visit http://tempothera.com/
Contact:
Westbrook Weaver, Chief Executive Officer
251-654-4070
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.